Ajinomoto Co. has developed an innovative direct chemical site-selective conjugation method intended for use with intact native antibodies. AJICAP™ technology is a novel platform for the site-selective conjugation of antibodies using a class of Fc-affinity compounds to install payload-compatible linkers to well-defined amino acid residue(s). The wide compatibility of the native antibody allows for well tolerated modifications (if required). With the broad drug-linker compatibility of AJICAP™ -- Azide as well as Thiol functionality can be introduced. The therapeutic window has been enhanced with improvements demonstrated in pharmacokinetic analysis and efficacy. AJICAP™ technology promotes a more straightforward manufacturing process with increased productivity and shorter conjugation reaction times. This poster series illustrates the AJICAP™ technology story.